Skip to content
10-Q

Quarterly Report

Rapid Therapeutic Science Laboratories, Inc.

0001393905-21-000494

← back to feed
Filed
Nov 10, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2021 · Nov 9, 2021 193.57M sh
Cash And Equivalents Q3 2021 · Sep 30, 2021 $919.71K
Cash And Equivalents Q3 2021 · Dec 31, 2020 $499.15K
Cash And Equivalents Q3 2021 · Sep 30, 2020 $266.06K
Cash And Equivalents Q3 2021 · Dec 31, 2019 $125.13K
Stockholders Equity Q3 2021 · Sep 30, 2021 −$166.95K
Stockholders Equity Q3 2021 · Dec 31, 2020 −$11.2K
Current Liabilities Q3 2021 · Sep 30, 2021 $2.05M
Current Liabilities Q3 2021 · Dec 31, 2020 $1.21M
Total Liabilities Q3 2021 · Sep 30, 2021 $2.2M
Total Liabilities Q3 2021 · Dec 31, 2020 $1.52M
Current Assets Q3 2021 · Sep 30, 2021 $1.16M
Current Assets Q3 2021 · Dec 31, 2020 $685.95K
Total Assets Q3 2021 · Sep 30, 2021 $2.03M
Total Assets Q3 2021 · Dec 31, 2020 $1.51M
Capex Q3 2021 · Sep 30, 2020 $92.98K
Operating Cash Flow Q3 2021 · Sep 30, 2020 −$1.14M
Sga Expense Q3 2021 · Sep 30, 2020 $593.16K
Sga Expense Q3 2021 · Sep 30, 2020 $1.45M
Net Income Q3 2021 · Sep 30, 2020 −$640.54K
Net Income Q3 2021 · Sep 30, 2020 −$1.52M
Net Income Q3 2021 · Jun 30, 2020 −$566.38K
Net Income Q3 2021 · Mar 31, 2020 −$311.15K
Gross Profit Q3 2021 · Sep 30, 2020 −$3.16K
Gross Profit Q3 2021 · Sep 30, 2020 $109.55K
Cost Of Revenue Q3 2021 · Sep 30, 2020 $4.79K
Cost Of Revenue Q3 2021 · Sep 30, 2020 $30.5K
Revenue Q3 2021 · Sep 30, 2020 $1.63K
Revenue Q3 2021 · Sep 30, 2020 $140.06K